Top segments and regional performance

Last year, the company generated ‪36.75 B‬ USD, the most of which — ‪35.15 B‬ USD — came from its top-performing segment, Human Therapeutics, compared to ‪32.03 B‬ USD the previous year. The greatest contribution came from United States, which accounted for ‪26.42 B‬ USD last year, with ‪23.86 B‬ USD the year before.